Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00282360

Enrollment

Registered

2006-01-26

Start date

1999-02-28

Completion date

2003-10-31

Last updated

2006-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Type II Diabetes Mellitus

Keywords

coronary artery disease, diabetes mellitus

Brief summary

Patients with coronary artery disease have an abnormal cardiac metabolism. The hypothesis of this study is that shifting cardiac metabolism from free fatty acids to glucose will improve myocardial ischemia

Detailed description

The present study will evaluate the effect of free fatty acid inhibition with Trimetazidine on silent myocardial ischemia and total ischemic burden in coronary artery disease patients with type II diabetes. Patients will undergo ambulatory ECG monitoring at baseline and will be randomized to receive on top of thei standard anti-anginal therapy trimetazidine or placebo for 6 months. Patients will repeat the ambulatory ECG monitoring at the end of the study

Interventions

DRUGTrimetazidine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

coronary artery disease type II diabetes mellitus -

Exclusion criteria

unstable coronary artery syndromes impaired liver and kidney function \-

Design outcomes

Primary

Measure	Time frame
total ischemic burden	—
silent ischemia	—

Secondary

Measure	Time frame
symptomatic myocardial ischemia	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026